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In mammals, cGMP is generated by soluble and mem-
brane-bound guanylyl cyclases and can be degraded by
altogether eight out of 11 mammalian PDE families. Apart
from cGMP-activated protein kinases and from cGMP-
gated cation channels 5 of the 11 PDE families are also
subject to regulation by cNMP via their N-terminal tan-
dem GAF ensembles. Four, PDE 2, 5, 6, and 11 appear to
be regulated by cGMP; PDE10 is similarly regulated by
cAMP. Thus, the cyclic nucleotides act as allosteric activa-
tors which enhance their own degradation at the catalytic
site, i.e. they concomitantly serve as modulators of
enzyme activity and as substrates. This creates a biochem-
ical conundrum which cannot be disentangled kinetically.
We use a cyanobacterial adenylyl cyclase, cyaB1, as a
reporter enzyme to characterize intramolecular GAF
domain signalling. This cyclase has an N-terminal GAF
tandem which is similar to those in mammalian PDEs and
regulates cyclase activity in a feed-forward manner using
the product cAMP as an activator. Surprisingly, the GAF
tandem domains of PDE 2, 5, 10, and 11 functionally cou-
ple to the cyclase and regulate it in a manner consistent
with their function in the respective PDEs [1-3].
We show that the N-terminal domains which precede the
PDE GAF domains in PDE5 and PDE11 greatly affect GAF
domain signalling and, thus, likely participate in intramo-
lecular signalling [2,3]. For example, the GAF tandem of
PDE11 has a low cGMP affinity (EC50 = 72 μM) i.e. in a
non-physiological concentration range. However, short-
ening the 196 aa long N-terminus by 177 aa lowers the
EC50 for cGMP to 3.5 μM, well in a physiologically mean-
ingful range. A cysteine protease present in human tissues
such as prostate, kidney, bladder, skeletal muscle, heart,
and uterus restricts the N-terminus of PDE11 and may
represent an additional layer of PDE regulation.
In PDE10 the allosteric activator is cAMP whereas in all
other mammalian PDEs of this sub-family cGMP serves as
an activator. Mutational studies indicated that the PDE 10
GAF tandem domain signals via its GAF-B region like
PDE2 whereas the GAF tandem of PDE5 signals via its
GAF-A region. We generated hybrid chimeras between the
GAF tandems of PDE 5, binding cGMP, and PDE 10, bind-
ing cAMP, in order to investigate whether we would
obtain a GAF tandem capable of signalling by cGMP via
GAF A and by cAMP via GAF B. This was not unequivo-
cally accomplished. However, we demonstrate that the
mode of signalling appears to be strongly affected by the
source of the α-helix which connects the GAF-A and GAF-
B regions. A hybrid construct comprised of the N-terminal
and GAF-A from PDE5 and the linker and GAF-B from
PDE10 could be stimulated by cAMP and, to a lesser
extent, by cGMP. However, a similar construct in which
the linker between GAF-A (from PDE5) and B (from
PDE10) was from the PDE 5 was unresponsive to both,
cGMP and cAMP. Apart from the unresolved question
how in the GAF domains cNMP specificity is encoded this
highlights the importance of the linker region for the for-
mation of a functional tandem GAF complex [unpub-
lished].
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